
Physicists Catch ‘Ghost Particles' Bouncing Off Matter in Record-Breaking Experiment
When a low-energy neutrino bounces off the entire nucleus of an atom, the resulting scattering produces sufficient signals for physicists to capture at a nuclear reactor. Using this concept, physicists successfully measured the lowest-ever energy levels recorded in neutrino events, reporting their results in a Nature paper published today. For the experiment, the Coherent Neutrino Nucleus Scattering (CONUS+) collaboration, based in Leibstadt, Switzerland, effectively 'hatched' antineutrinos from inside a nuclear reactor.
'This was a big experimental challenge,' Christian Buck, study co-author and physicist at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany, told Gizmodo.
This detector picks up signals from the recoil energy created when antineutrinos bounce off an atomic nucleus. Since matter and antimatter share most fundamental properties, the same measurements can be used to characterize the energy levels of neutrinos. The main detector weighs just 6.6 pounds (3 kilograms), which is tiny compared to typical ton-scale neutrino detectors. Having such a compact neutrino detector offers tantalizing opportunities for more mobile investigations into neutrinos and atomic structures in general, according to the researchers.
Formally, neutrinos bouncing off an entire nucleus is called coherent elastic neutrino-nucleus scattering (CEvNS), first predicted in 1974. Physicists surmised that CEvNS should feature interaction rates 100 to 1,000 times higher than the typical approach of waiting for a neutrino to brush past one of the millions of particles zipping inside giant detectors. In contrast, CEvNS is like 'a tiny neutrino giving the nucleus just a gentle bump, like a ping-pong ball hitting a car, and now we have to detect the movement of the car,' Buck explained.
It wasn't until 2017 that the COHERENT experiment at Oak Ridge National Laboratory confirmed this was possible using a particle accelerator. CONUS+ and its predecessor, CONUS, build on that result with some significant modifications: measuring CEvNS using a nuclear reactor as a source to demonstrate an entirely new interaction channel to study neutrinos.
'For the reactor operators, this is just an unnecessary side product that they do not need to care about,' Buck said. 'For us, the reactor is a free, point-like source of the antineutrinos—a reactor like the one in Leibstadt emits 10 to the power of 21 antineutrinos each second! Almost all of them pass matter without any effect (like a ghost), but we try to catch a few of them per day.'
'After two decades of experimental efforts, the search for CEvNS has progressed into the era of precision measurements,' Henry T. Wong, a physicist at the Institute of Physics, Academia Sinica, in Taiwan, wrote in an accompanying News & Views article for Nature. The latest results from CONUS+ will 'raise high hopes among neutrino-physics researchers,' Wong, who wasn't involved in the study, added.
As an important next step, CONUS+ will attempt to increase the precision of its device even further and apply its findings to practical real-world applications. Its unique location inside a nuclear reactor has already garnered interest from major organizations, such as the International Atomic Energy Agency, according to Buck.
'In principle, such a detector can be used to monitor the thermal power or the evolution of the reactor fuel over time,' he explained. 'We have now made the first step…but for sure there are still several years and steps ahead of us before the technology is ready for commercial applications.'
More importantly, the new technique may potentially turn up some phenomena at odds with what we know of the Standard Model, Buck said. If so, 'this could be a hint that our understanding is not complete and that new particles or so far not-known interactions are at play,' he said.
When I first came across this result, my editor and I had a quick discussion about the nature of antineutrinos. If neutrinos are popularly referred to as 'ghost particles,' would that make antineutrinos…anti-ghost particles? What does that even mean?
I had to ask Buck for his thoughts. His answer: 'Since antineutrinos are very similar to neutrinos, an antineutrino is more or less like a neutrino in a mirror. I see them in one category. There are conservation laws in physics that allow some reactions only for the one or the other, but they are both of similar importance.'
Though, he added, one hot topic in the field concerns whether there's a fundamental difference between neutrinos and antineutrinos. If physicists are able to answer this question, perhaps we'll know for sure if antineutrinos are ghosts in the mirror or (although unlikely) something else altogether.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Ministers urged to tackle surge in Asian hornets after rise in sightings
This year could be the worst ever for Asian hornets in the UK, scientists are warning, after a rise in sightings of the invasive insect. The National Bee Unit says there were 73 credible sightings up to the end of last month – more than double the 28 recorded in the same period last year. Experts from the unit have also found 28 nests so far this year. One nest can house up to 3,000 of the insects. Asian hornets, also known as yellow-legged hornets, can badly harm native pollinator insects, including honeybees, threatening food security and ecosystems, ecologists say. The species was sighted in record numbers in the UK in 2023, and last September UK experts saw evidence for the first time of the queens over-wintering. In May this year, their numbers were described as unprecedented. The Liberal Democrats have accused the government of not taking the issue seriously enough and are calling for a task force to deal with the problem. Martin Wrigley, MP for Newton Abbot in Devon, told The Telegraph: 'The previous Conservative government was asleep at the wheel in their response to Asian hornets so the government has got to wake up to the risks and get a grip on this invasive species now – especially ahead of August and September, when new females are born. 'We urgently need a fully fleshed task force dedicated to this invasive insect to reduce delays between reporting nests and their destruction. It's time this government took our biodiversity and the safety of our communities seriously.' The species, which spread from Asia to Europe in a pottery consignment sent to France in 2004, was first spotted in Britain in 2016, and numbers have been rising since. The UK Centre for Ecology & Hydrology (UKCEH) has warned that without early detection and a rapid response, the species could gain a foothold in the UK. Sightings usually peak from September, and people are urged to report any sightings on the Asian Hornet Watch app. Ian Campbell, of the British Beekeepers Association, said that this year appeared to be a 'surge year' for yellow-legged hornets, in part because of the weather. 'There is significant worry that this year is going to be ahead of 2023, which is the worst year we've had so far,' he said. He called for authorities to try to eradicate the species before it became fully established. The invasive species is mostly found in Kent and East Sussex but has also been seen in Surrey, Hampshire and London, and even as far as Co Durham. It's thought they come into the country on vehicles. Ecologists say that except for parts of Scotland, all of Britain has a suitable climate for yellow-legged hornets. Asian hornets also have a dark abdomen with a band of yellow, while native hornets' abdomens are predominantly yellow. A spokesman for the Animal and Plant Health Agency told The Telegraph: 'Our highly skilled staff work 24/7 to tackle the threat of invasive non-native species, which cost the economy nearly £2bn a year. 'The yellow-legged hornet response, as with other outbreaks, is managed through a roster of trained nest destructors and inspectors that is scaled up as required based on reports and seasonal fluctuations.' They said it was not unexpected to see more reports of sightings as public awareness of the insects increased. A spokesman for Defra said the government would 'never waver in its duty to protect the UK's biosecurity' and pointed to its establishment of a new £200m biosecurity centre and an additional £10m for new surveillance projects.
Yahoo
5 hours ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Experiment Recreates The Universe's Very First Chemical Reactions
The first chemical reactions in the wake of the Big Bang have been recreated for the first time in conditions similar to those in the baby Universe. A team of physicists Led by Florian Grussie of the Max Planck Institute for Nuclear Physics (MPIK) in Germany has reproduced the reactions of helium hydride ion (HeH+), a molecule made from a neutral helium atom fusing with an ionized atom of hydrogen. These are the first steps that lead to the formation of molecular hydrogen (H2); the most abundant molecule in the Universe and the stuff from which stars are born. The new work, therefore, elucidates some of the earliest processes that gave rise to the Universe as we know it today. Related: The First Molecular Bond in The Universe Has Finally Been Detected in Space The birth throes of the Universe some 13.8 billion years ago produced a hot, dense soup of fundamental particles simmering at temperatures too high for atoms to form. It took about 380,000 years for nuclei and electrons to lose enough energy to congeal into the very first elements. Those elements were the lightest the periodic table has to offer; about 75 percent hydrogen, 25 percent helium, and trace amounts of lithium. Hydrogen continues to dominate the Universe's ingredient list today, as clouds of molecular gas that give birth to the stellar furnaces from which the heavier elements are born, either through fusion or violent explosions. None of that, however, could happen without HeH+ – a molecule that scientists believe played a huge role in cooling the Universe enough so that the molecular clouds could contract enough to attain the density required to collapse under their own gravity to form the seeds of baby stars. That's because HeH+ has a comparatively large separation between its positive and negative charges. In the presence of an electric field, a molecule with a large charge separation undergoes an energy shift that helps dissipate heat, which means HeH+ theoretically played a key role in paving the way for the formation of the first stars. The researchers performed their experiments at the Max Planck Institute's Cryogenic Storage Ring, a facility designed to perform experiments in a vacuum environment at temperatures just a few degrees above absolute zero, around -267 degrees Celsius (-449 Fahrenheit), mimicking the conditions of deep space. There, they carefully studied interactions between HeH+ and a hydrogen atom with one extra neutron in its nucleus, known as deuterium. An interaction between HeH+ and deuterium generates a neutral helium atom and a molecule consisting of one neutral hydrogen atom and one charged deuterium atom (HD+), with lower energy levels than the original components. Within the storage ring, the researchers fired two beams of particles; one with HeH+ molecules, the other with neutral deuterium. They changed the speed of the two beams to alter the energy at which the particles collided as a proxy for temperature to see if temperature played a role in the reaction rate. It did not. The rate at which the reaction took place remained steady, regardless of the proxy temperature – suggesting that the role HeH+ played in the early Universe did not decline as cooling unfolded, and that its role in the formation of the first generation of stars was a significant one. "Previous theories predicted a significant decrease in the reaction probability at low temperatures, but we were unable to verify this in either the experiment or new theoretical calculations by our colleagues," physicist Holger Kreckel from the MPIK explains. "The reactions of HeH+ with neutral hydrogen and deuterium therefore appear to have been far more important for chemistry in the early Universe than previously assumed." The research has been published in Astronomy & Astrophysics. Related News Scientists Just Admitted Nobody Really Gets Quantum Physics First Quantum Bit Made of Antimatter Captured in Physics Breakthrough Gold Does Something Unexpected When Superheated Past Its Melting Point Solve the daily Crossword